Loading…
Employees: 2,634
Size Boiron (BOI.PA) is a France Health Care company (Pharmaceuticals: Other) with a market value of $391M, the 189th largest of 206 France companies the cockpit tracks. Shares closed at €19.90 on 6 Nov 2026.
Performance Over six months the shares fell 31.4%, against -21.2% for the median peer and -0.4% for the France market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 1.8% over the last twelve months (peer median -3.3%); the operating margin is 5.2% (peer median 14.2%).
Valuation It trades at 9.7× forward earnings against a peer median of 16.9× (2nd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.9 points below its cost of capital (6.3% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €496M | €501M | €488M | €493M | €534M |
| Revenue growth | — | +3% | -1% | -8% | — |
| Gross profit | €358M | €366M | €359M | €358M | €380M |
| EBITDA | €56.7M | €66.3M | €65.8M | €72.8M | €87.7M |
| Net income | €26.2M | €32.6M | €11.3M | €35.8M | €44.7M |
| Free cash flow | €25.8M | €40.2M | €33.8M | €42.3M | €49.9M |
| Capital expenditure | €26.2M | €23.5M | €15.9M | €18.0M | €18.6M |
| Total debt | n/a | €31.5M | €15.0M | €13.7M | €22.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BOI.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.4% | -9.1% | highest of 21 |
| 6-month return | -31.4% | -21.2% | 2nd lowest of 21 |
| Distance from 52-week high | -38.3% | -38.7% | 11th highest of 21 |
| Revenue growth (TTM) | -1.8% | -3.3% | 9th highest of 19 |
| Operating margin | 5.2% | 14.2% | 8th lowest of 20 |
| Forward P/E | 9.7× | 16.9× | 2nd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | -0.3% | 2.4% | 5th least demanding of 15 |
| Growth delivered (Del g) | -0.5% | +6.5% | 4th lowest of 14 |
| Hurdle (Req g minus delivered) | +0.2 pp | -3.0 pp | 6th most demanding of 14 |
| ROIC minus cost of capital | -0.9 pp | +0.1 pp | 7th lowest of 19 |
| EV / EBITDA | 5.7× | 10.4× | 3rd cheapest of 5 |
| Net debt / EBITDA | -0.5× | -3.4× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Boiron BOI.PA | France | $391M | -31% | -2% | 5% | 9.7× | -0.3% | -0.5% |
| Grape King Bio 1707.TW | Taiwan | $361M | -28% | -7% | 20% | 11.0× | -18.9% | +2.3% |
| Tibet Aim Pharm 002826.SZ | China | $427M | -23% | +13% | 14% | n/a | 1.3% | +1.0% |
| Daiken Biomedical 7780.TW | Taiwan | $352M | -24% | n/a | 18% | n/a | 0.3% | n/a |
| Zhejiang Xinguang Pharmaceutical 300519.SZ | China | $349M | -11% | +5% | 27% | n/a | 5.2% | -1.3% |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | n/a | -14.7% | +8.9% |
| TCI 8436.TWO | Taiwan | $320M | -24% | -2% | 18% | 10.0× | -13.0% | -3.2% |
| Weihai Baihe Biology Technological 603102.SS | China | $314M | -20% | +18% | 14% | 17.6× | -10.2% | +9.6% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | n/a | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | n/a | 3.0% | +7.0% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | n/a | 24.3% | +6.5% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 48.6× | 20.4% | +12.1% |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 438.0× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | n/a | n/a | n/a |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |